Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07821658) titled 'A Postmarketing Study of Lecanemab for the Treatment of Participants With Alzheimer's Disease' on Sept. 9.

Study Type: Observational

Primary Sponsor: Eisai Inc.

Condition: Alzheimer's Disease

Intervention: Other: No Intervention

Recruitment Status: Recruiting

Date of First Enrollment: May 23, 2025

Target Sample Size: 6700

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07821658

Published by HT Digital Content Services with permission from Health Daily Digest....